Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Suppression Induite de l'Activité Plaquettaire dans la Prise en Charge de l'Hémorragie Sous-Arachnoïdienne Anévrismale-2 (iSPASM-2) (iSPASM-2)

2 novembre 2026 mis à jour par: Dr David Hasan, M.D.

Suppression Induite de l'Activité Plaquettaire dans la Prise en Charge de l'Hémorragie Sous-Arachnoïdienne Anévrismale-2

An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.

Aperçu de l'étude

Statut

Pas encore de recrutement

Description détaillée

This is an exploratory, two-center, randomized, double-blinded study. The primary objective is to determine the maximum tolerated dosage (MTD) of tirofiban in the context of patients with aSAH status post-endovascular coiling. The dosage regimen of tirofiban will be 0.10µg/kg/min (actual weight) within 48 hours of aneurysm securing and within 72 hours of ictus.

The study will involve a dose escalation stage and a cohort expansion stage. During the dosage-escalation stage, the intervention doses include continuous intravenous (IV) tirofiban or IV placebo for 1 day, 3 days, 5 days, or 7 days. Dose-escalation will follow the time-to-event Bayesian Optimal Intervention (TITE-BOIN) design. Unlike the majority of existing phase I designs, which require suspending the accrual after treating each cohort of patients, the TITE-BOIN design allows for real-time dose assignment decisions for new patients while the toxicity data are still pending for some patients under treatment. This shortens the trial duration and reduces the logistical difficulties caused by frequent suspensions of accrual. For parallel comparison under real-world conditions, patients will be randomly assigned to tirofiban and placebo in a 2:1 ratio in the dose escalation stage. The data from the placebo patients will not be analyzed to inform dose escalation but included in the final analysis upon study completion. Upon the completion of the dose escalation stage, the MTD will be selected using isotonic regression. MTD will be selected as the dosage for which the isotonic estimate of the toxicity rate is closest to the target dosage-limiting toxicity rate (30%). If there is a tie, we will select the higher dosage level when the isotonic estimate is lower than the target toxicity rate, and we will select the lower dosage level when the isotonic estimate is greater than or equal to the target toxicity rate.

During the cohort expansion stage, patients will be randomized to tirofiban at MTD and placebo at the corresponding dosage level to achieve balanced sample sizes (30 tirofiban at MTD and 30 placebo for any infusion duration, combined from both phases) across the two groups. The analysis of the exploratory endpoints will be performed on the tirofiban patients at MTD and placebo patients with any infusion duration.

An interim pharmacokinetic (PK) analysis will be performed after 10 evaluable patients are treated with tirofiban to determine possible dose modification. At the completion of the study, PK and pharmacodynamic (PD) analysis will be conducted using all evaluable patients treated with tirofiban to determine whether augmented renal clearance in aSAH interacts with the pharmacokinetics and pharmacodynamics of tirofiban.

Type d'étude

Interventionnel

Inscription (Estimé)

82

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • North Carolina
      • Durham, North Carolina, États-Unis, 27710
        • Duke University Health System
        • Contact:
        • Contact:
        • Chercheur principal:
          • Emad Hasan, MD
        • Chercheur principal:
          • Brian Mac Grory, MD
    • Texas
      • Houston, Texas, États-Unis, 77030
        • University of Texas Health Sciences Center
        • Contact:
        • Chercheur principal:
          • Spiros Blackburn, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 85 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion:

  • Age 18-85
  • Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH)
  • SAH attributed to ruptured cerebral aneurysm
  • Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space
  • World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization
  • Onset of symptoms of aSAH (ictus) occurred <72 hours prior to presentation
  • If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment
  • All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment
  • Participant can be randomized within 48 hours of aneurysm treatment
  • Participant or participant's legally-authorized representative (LAR) has provided documented informed consent

Exclusion:

  • Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm

  • Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment

  • Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern

  • Uncontrollable hypertension (>180 systolic and/or >110 diastolic) that is not correctable prior to enrollment

  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days)

  • A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion

  • New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT

  • Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase)

  • Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation

  • Thrombocytopenia (platelet count <100,000/microliter (µL) assuming clumping is ruled out

  • Allergy or intolerance to tirofiban

  • Pregnant or lactating

  • Chronic kidney disease with creatinine clearance (CrCl ≤ 30 milliliters per minute [ml/min]) or acute kidney injury (AKI) at study screening. AKI is defined as:

    i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg/dL) or more (26.5 micromoles per liter [μmol/L] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml/kg/hour for at least 6 hours

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Tirofiban

Continuous IV infusion of tirofiban for 1, 3, 5, or 7 days post-endovascular coiling.

IV infusion at 0.10 microgram/kilogram/minute (mcg/kg/min) for 1 day, 3 days, 5 days, or 7 days according to the dose escalation procedure.

Autres noms:
  • Aggrastat ®
Comparateur placebo: Placebo

Continuous IV infusion of saline placebo for 1, 3, 5, or 7 days post-endovascular coiling.

IV infusion at the same infusion duration as the study drug; same adjustments

Autres noms:
  • Solution saline normale

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Tirofiban dosage-limiting toxicity (DLT)
Délai: Within 14 days post-randomization

Presence of any of the following: any intracranial hemorrhage, major extracranial hemorrhage (defined as clinically overt bleeding leading to death; OR clinically overt bleeding causing a reduction in hemoglobin of ≥2g/dl; OR clinically overt bleeding necessitating transfusion of ≥2 units of packed red cells or whole blood; OR clinically overt bleeding in a critical area or organ other than the intracranial compartment (including intraspinal, intraocular, pericardial, intra-articular, retroperitoneal, intramuscular [with compartment syndrome])), thrombocytopenia, or serious adverse event (SAE) due to tirofiban.

Within 14 days post-randomization

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Paramètres pharmacocinétiques - clairance totale (Cltot)
Délai: Jusqu'à 7 heures après l'arrêt du médicament
Jusqu'à 7 heures après l'arrêt du médicament
Paramètres pharmacocinétiques - Volume de distribution (Vd)
Délai: Jusqu'à 7 heures après l'arrêt du médicament
Jusqu'à 7 heures après l'arrêt du médicament
Pharmacokinetic parameters - Maximum (peak) plasma concentration (Cmax)
Délai: Up to 7 hours after drug discontinuation

Highest concentration of tirofiban in the blood after a dose is administered

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Minimum (trough) plasma concentration (Cmin)
Délai: Up to 7 hours after drug discontinuation

Lowest observed concentration of tirofiban in the blood after a dose is administered

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Average Plasma Concentration (Cavg)
Délai: Up to 7 hours after drug discontinuation

Average tirofiban concentration in the blood at steady state

Up to 7 hours after drug discontinuation
Pharmacokinetic parameters - Area Under the Concentration (AUC)Time Curve
Délai: Up to 7 hours after drug discontinuation

Area under the curve from time 0 extrapolated to infinite time

Up to 7 hours after drug discontinuation
Pharmacodynamic parameters - adenosine diphosphate (ADP)
Délai: Baseline, 2, 6, and every 24 hours and at drug cessation

The percent inhibition of ADP-induced platelet aggregation

Baseline, 2, 6, and every 24 hours and at drug cessation

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Delayed cerebral ischemia (DCI) or death without DCI
Délai: Within 14 days post-randomization

This is the primary exploratory efficacy outcome, which is a composite binary outcome. DCI is defined as any of the following: a. Focal neurological impairment, b. decrease of at least 2 points on the Glasgow coma scale and/or c. cerebral infarction present on final CT or MRI, which was not present on a CT or MRI between 24-48 hours post-endovascular therapy and not attributable to other causes.

Within 14 days post-randomization
Cerebral vasospasm
Délai: Within 14 days post-randomization or until discharge from the index admission, which occurred later

Cerebral vasospasm requires confirmation of vasospasm on either CTA or DSA confirming mild vasospasm (decrease in vessel diameter by ≤25% of normal artery diameter), moderate vasospasm (decrease in vessel diameter by >25 to ≤50% of normal diameter but cerebral vasospasm), or severe vasospasm (decrease in vessel diameter by >50% of normal vessel diameter)

Within 14 days post-randomization or until discharge from the index admission, which occurred later
Mortality
Délai: 3 and 6 months post-randomization

Death of any cause

3 and 6 months post-randomization
Total number of days in the ICU for the index admission
Délai: Up to 6 months post-randomization

Total number of days from ICU admission to ICU discharge during the index hospitalization

Up to 6 months post-randomization
Total hospital stay length for the index admission
Délai: Up to 6 months post-randomization

Total number of days from admission to discharge during the index admission

Up to 6 months post-randomization
Modified Rankin Scale (mRS)
Délai: 3 and 6 months post-randomization

It is a clinician-reported measure of global disability, widely applied for evaluating stroke patient outcomes and as an endpoint in randomized clinical trials. It is a single-item 7-point scale with a range of 0 (no symptoms at all) to 6 (death), with higher scores indicating greater disability.

The elements of the mRS are as follows: (1) no symptoms at all; (2) no significant disability, but there may be slight symptoms such as weakness or numbness; (3) slight disability, but able to carry out daily activities independently; (4) moderate disability, requiring some help with daily activities; (5) moderately severe disability, requiring assistance with most daily activities; (6) severe disability, bedridden and requiring constant nursing care; and (7) death.

3 and 6 months post-randomization
Return to work
Délai: 3 and 6 months post-randomization

Returned to prior level of responsibilities at work

3 and 6 months post-randomization
Lawton Instrumental Activities of Daily Living (Lawton IADL)
Délai: 3 and 6 months post-randomization

It is an instrument to assess independent living skills among older adults, and can be used in community or hospital settings. There are 8 domains of function measured with the scale: (1) using the telephone; (2) shopping; (3) preparing food; (4) housekeeping; (5) doing laundry; (6) using transportation; (7) handling medications; (8) handling finances.

Women are scored on all 8 areas of function; historically, for men, the areas of food preparation, housekeeping, and laundering are excluded. Individuals are scored according to their highest level of functioning in that category. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men.

3 and 6 months post-randomization
Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS)
Délai: 3 and 6 months post-randomization

It is a 6-item scale to evaluate the overall satisfaction with facets of life relevant to people with traumatic brain injury. The area covered by the questionnaire includes physical condition, cognition, emotions, function in daily life, personal and social life, and current situation and future prospects.

Responses to each item were scored 1 ('Not at all') to 5 ('Very'), and the sum of all items was converted arithmetically to a percentage scale, with 0 representing the lowest possible (health-related quality of life (HRQoL) on the questionnaire and 100 the best possible HRQoL.

3 and 6 months post-randomization
Glasgow Outcome Scale-Extended (GOS-E)
Délai: 3 and 6 months post-randomization

It is used to assess global outcomes in persons with brain injury, by categorizing global function using an 8-point ordinal scale that focuses on disability and functioning in daily life. The scales are: 1. Dead, 2. Vegetative State, 3. Lower Severe Disability (SD), 4. Upper SD, 5. Lower Moderate Disability (MD), 6. Upper MD, 7. Lower Good Recovery (GR), 8. Upper GR

3 and 6 months post-randomization
PROMIS-29+2
Délai: 3 and 6 months post-randomization

The Patient-Reported Outcomes Measurement Information System® (PROMIS) is a flexible set of tools designed to measure self-reported physical, mental, and social health and wellbeing. PROMIS-29+2 is a collection of 4-item Likert-item short forms assessing the following domains:

  1. Physical function
  2. Anxiety
  3. Depression
  4. Fatigue
  5. Sleep disturbance
  6. Ability to participate in social roles and activities
  7. Pain interference
  8. Cognitive Function - Abilities (2 items)
  9. Pain intensity (single item)

Norm-based scores will be calculated for each domain on the PROMIS measures, so that a score of 50 represents the mean or average of the reference population. A score of 60 means that the person is one standard deviation above the reference population (standard deviation = 10). For PROMIS measures, higher scores equal more of the concept being measured (e.g., more Fatigue, more Physical Function).

3 and 6 months post-randomization
Montreal Cognitive Assessment (MoCA)
Délai: 3 and 6 months post-randomization

It is a 30-point test to assess people for dementia. The MoCA evaluates different types of cognitive abilities, including orientation, short-term memory / delayed recall, executive function / visuospatial ability, language ability, abstraction, animal naming, attention, and clock-drawing. Scores range from 0 to 30, with a score of 26 or higher considered normal.

3 and 6 months post-randomization

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Emad Hasan, MD, Duke University
  • Chercheur principal: Brian Mac Grory, MD, Duke University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

5 décembre 2026

Achèvement primaire (Estimé)

5 mai 2029

Achèvement de l'étude (Estimé)

5 mai 2032

Dates d'inscription aux études

Première soumission

10 mars 2026

Première soumission répondant aux critères de contrôle qualité

23 mars 2026

Première publication (Réel)

25 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner